Stalevo: Difference between revisions

From SEHK Wiki
Zeki (talk | contribs)
No edit summary
Zeki (talk | contribs)
No edit summary
 
(3 intermediate revisions by the same user not shown)
Line 1: Line 1:
[[Category: Drugs]][[Category: Catechol-O-methyltransferase inhibitor]]
[[Category: Drugs]][[Category: Dopaminergic Antiparkinsonian agent]][[Category: Catechol-O-methyltransferase inhibitor]]


[[:Category: Antiparkinsonian Drug | '''Antiparkinsonian Drug''']]
[[:Category: Antiparkinsonian Drug | '''Antiparkinsonian Drug''']]


'''Drug class: [[:Category: Catechol-O-methyltransferase inhibitor | Catechol-O-Methyltransferase Inhibiotr, COMT Inhibitor]]
'''Drug class: [[:Category: Dopaminergic Antiparkinsonian agent | Dopaminergic Antiparkinsonian Agent]]''' and is categorized as a combination of '''[[:Category: Decarboxylase Inhibitors | decarboxylase inhibitors]]''' and '''[[:Category: Catechol-O-methyltransferase inhibitor | Catechol-O-methyltransferase Inhibitor, COMT Inhibitor]]'''


'''Carbidopa + Etacapon + Levodopa (STALEVO)'''
'''Carbidopa, Etacapon and Levodopa (STALEVO)'''(中文:[[始立]])
==Pronunciation==
==Pronunciation==
===Stalevo 100mg===
===Stalevo 100mg===
[[File:Stalevo 100mg.mp3]]
[[File:Stalevo 100mg.mp3]]
==Common Strengths of Stalevo==
Stalevo is available in six strengths, each containing a specific ratio of its components:
*Stalevo 50: 12.5 mg carbidopa, 50 mg levodopa, 200 mg entacapone
*Stalevo 75: 18.75 mg carbidopa, 75 mg levodopa, 200 mg entacapone
*Stalevo 100: 25 mg carbidopa, 100 mg levodopa, 200 mg entacapone
*Stalevo 125: 31.25 mg carbidopa, 125 mg levodopa, 200 mg entacapone
*Stalevo 150: 37.5 mg carbidopa, 150 mg levodopa, 200 mg entacapone
*Stalevo 200: 50 mg carbidopa, 200 mg levodopa, 200 mg entacapone
==Drug Trade Name==
The primary trade name for this medication is Stalevo.
==Drug Usage==
Stalevo is used to treat symptoms of Parkinson's disease, including tremors, stiffness, and difficulty with movement. It dose not cure the disease but helps manage its symptoms.
==Mechanism of Action==
Stalevo consists of three active ingredients: carbidopa, levodopa, and entacapone.
The mechanism involves:
*Levodopa converting to dopamine in the brain.
*Carbidopa prevents the premature conversion of levodopa to dopamine outside the brain.
*Entacpone inhibits the COMT enzyme to prolong the effect of levodopa by preventing its breakdown.
==Route of Administration==
Stalevo is administered orally, typically as a film-coated tablet.
==Dosages==
Dosage adjustments depend on individual patient needs and conditions.
==Side Effects==
{| class="wikitable"
!style="text-align: left"| Frequency
!Adverse reactions
|-
| rowspan="3" | '''Common Side Effects
| Nausea
|-
| Dizziness
|-
| Dyskinesia
|-
| rowspan="3" | '''Serious Side Effects
| Neuroleptic Malignant Syndrome (NMS)
|-
| Severe allergic reactions
|-
| Dark discoloration of urine or sweat
|}
==Pharmacokinetics==
The pharmacokinetics of Stalevo show:
*Peak concentrations for carbidopa at approximately 2.5 to 3.4 hours, while entacapone peaks at about 0.8 to 1.2 hours post-administration.
*The duration of action can vary but generally lasts several hours depending on individual metabolism and dosage.
==Drug Precautions==
'''Pregnancy
Stalevo falls under Category C; risks versus benefits should be evaluated before use during pregnancy.
'''Breastfeeding
Caution is advised; consult a healthcare provider regarding risk to the infant.
'''Drug Monitoring Items
Regular monitoring includes:
*Blood pressure checks
*Renal function tests (eGFR)
*Monitoring for dyskinesias or other movement disorders, may occur or worsen with Stalevo. Regular assessments are necessary to determine if dosage adjustments are needed.
*Mental Health Monitoring: Patients should be closely observed for mental changes, including depression and suicidal tendencies.
*Impulse Control Disorders: Patients and caregivers should be informed about the risk of impulse control disorders, which can manifest as compulsive behaviors such as gambling or eating.
*INR Monitoring: For patients on warfarin, monitoring of INR levels is recommended when initiating Stalevo therapy due to potential interaction
'''Drug Interactions
Notable interaction include:
*Contraindications with MAO Inhibitors: Concurrent use with non-selective MAO inhibitors (like phenelzine) can lead to severe hypertension.
*Dopamine Antagonists: Medications such as antipsychotics and antiemetics may reduce the effectiveness of Stalevo.
*Tricyclic Antidepressants: These can increase the risk of hypertension and dyskinesia when used alongside Stalevo.
*Phenytoin and Papaverine: These drugs may diminish the therqpeutic efects of levodopa.
Food interactions:
*High-protein meals can impair the absorption of levodopa.
*Alcohol may exacerbate side effects like dizziness or drowsiness.
==FAQ==
'''How Should I Take the Tablet?
Usually with food to minimize gastrointestinal upset.
'''What Should I Avoid While Taking?
Avoid consuming high-protein meals close to dosing time as they may interfere with the absorption of levodopa.
'''What Happens if I Miss a Dose?
If you miss a dose, take it as soon as you remember unless it is close to the time for your next dose; do not double up on doses.

Latest revision as of 04:23, 14 October 2024


Antiparkinsonian Drug

Drug class: Dopaminergic Antiparkinsonian Agent and is categorized as a combination of decarboxylase inhibitors and Catechol-O-methyltransferase Inhibitor, COMT Inhibitor

Carbidopa, Etacapon and Levodopa (STALEVO)(中文:始立

Pronunciation[edit]

Stalevo 100mg[edit]

Common Strengths of Stalevo[edit]

Stalevo is available in six strengths, each containing a specific ratio of its components:

  • Stalevo 50: 12.5 mg carbidopa, 50 mg levodopa, 200 mg entacapone
  • Stalevo 75: 18.75 mg carbidopa, 75 mg levodopa, 200 mg entacapone
  • Stalevo 100: 25 mg carbidopa, 100 mg levodopa, 200 mg entacapone
  • Stalevo 125: 31.25 mg carbidopa, 125 mg levodopa, 200 mg entacapone
  • Stalevo 150: 37.5 mg carbidopa, 150 mg levodopa, 200 mg entacapone
  • Stalevo 200: 50 mg carbidopa, 200 mg levodopa, 200 mg entacapone

Drug Trade Name[edit]

The primary trade name for this medication is Stalevo.

Drug Usage[edit]

Stalevo is used to treat symptoms of Parkinson's disease, including tremors, stiffness, and difficulty with movement. It dose not cure the disease but helps manage its symptoms.

Mechanism of Action[edit]

Stalevo consists of three active ingredients: carbidopa, levodopa, and entacapone.

The mechanism involves:

  • Levodopa converting to dopamine in the brain.
  • Carbidopa prevents the premature conversion of levodopa to dopamine outside the brain.
  • Entacpone inhibits the COMT enzyme to prolong the effect of levodopa by preventing its breakdown.

Route of Administration[edit]

Stalevo is administered orally, typically as a film-coated tablet.

Dosages[edit]

Dosage adjustments depend on individual patient needs and conditions.

Side Effects[edit]

Frequency Adverse reactions
Common Side Effects Nausea
Dizziness
Dyskinesia
Serious Side Effects Neuroleptic Malignant Syndrome (NMS)
Severe allergic reactions
Dark discoloration of urine or sweat

Pharmacokinetics[edit]

The pharmacokinetics of Stalevo show:

  • Peak concentrations for carbidopa at approximately 2.5 to 3.4 hours, while entacapone peaks at about 0.8 to 1.2 hours post-administration.
  • The duration of action can vary but generally lasts several hours depending on individual metabolism and dosage.

Drug Precautions[edit]

Pregnancy

Stalevo falls under Category C; risks versus benefits should be evaluated before use during pregnancy.

Breastfeeding

Caution is advised; consult a healthcare provider regarding risk to the infant.

Drug Monitoring Items

Regular monitoring includes:

  • Blood pressure checks
  • Renal function tests (eGFR)
  • Monitoring for dyskinesias or other movement disorders, may occur or worsen with Stalevo. Regular assessments are necessary to determine if dosage adjustments are needed.
  • Mental Health Monitoring: Patients should be closely observed for mental changes, including depression and suicidal tendencies.
  • Impulse Control Disorders: Patients and caregivers should be informed about the risk of impulse control disorders, which can manifest as compulsive behaviors such as gambling or eating.
  • INR Monitoring: For patients on warfarin, monitoring of INR levels is recommended when initiating Stalevo therapy due to potential interaction

Drug Interactions

Notable interaction include:

  • Contraindications with MAO Inhibitors: Concurrent use with non-selective MAO inhibitors (like phenelzine) can lead to severe hypertension.
  • Dopamine Antagonists: Medications such as antipsychotics and antiemetics may reduce the effectiveness of Stalevo.
  • Tricyclic Antidepressants: These can increase the risk of hypertension and dyskinesia when used alongside Stalevo.
  • Phenytoin and Papaverine: These drugs may diminish the therqpeutic efects of levodopa.

Food interactions:

  • High-protein meals can impair the absorption of levodopa.
  • Alcohol may exacerbate side effects like dizziness or drowsiness.

FAQ[edit]

How Should I Take the Tablet?

Usually with food to minimize gastrointestinal upset.

What Should I Avoid While Taking?

Avoid consuming high-protein meals close to dosing time as they may interfere with the absorption of levodopa.

What Happens if I Miss a Dose?

If you miss a dose, take it as soon as you remember unless it is close to the time for your next dose; do not double up on doses.